Skip to main content

Table 1 PECOS criteria to outline the scope of the literature review

From: The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review

Population Including males with DMD in North America
Exposures/comparators Subgroup
Corticosteroid treatment
By age
By disease status at baseline
Outcomes Clinical/functional measures measured over a minimum of 1 yeara
Pulmonary function tests: Forced vital capacity, peak expiratory flow
Assessment of cardiac function: Ejection fraction, left ventricular end diastolic dimension, shortening fraction
Key clinical outcomes
Need for ventilatory support
Pulmonary dysfunction
Cardiac dysfunction/cardiomyopathy
Study design Prospective or retrospective studies
Case series
  1. DMD Duchenne muscular dystrophy, LOA loss of ambulation
  2. aOnly commonly reported functional assessments described in included studies are listed. Other functional assessments were searched (e.g. the 6-min walk test, North Star Ambulatory Assessment, Maximum inspiratory/expiratory pressure, Forced expiratory volume) but results to include in this manuscript were not identified